Melanoma
Conditions
Interventions
advanced melanoma patients who were treated with PD-1:none
Sponsors
Medical Department, Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who were diagnosed as unresectable or metastatic stage III/VI advanced melanoma between July 1, 2018 and June 30, 2023. 2.Received at least one dose of Toripalimab or Pembrolizumab, unlimited number of treatment lines, single or combination therapy 3.Baseline data is relatively complete 4.There is at least one subsequent medical record or survival follow up information by phone after PD-1 administration
Exclusion criteria
Exclusion criteria: 1.Patients who received PD-1 as postoperative adjuvant therapy 2.Patients with second primary malignancy 3.Patients are currently participating in interventional clinical trials involving Toripalimab or Pembrolizumab (but those who participate in other drug clinical trials before or after PD-1 treatment can be included). 4.Patients without any subsequent diagnosis and medical records after one dose of PD-1 administration. And Lost to follow up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progressive free survival, Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective remission rate;Safety;economy; | — |
Countries
China
Contacts
Public ContactQiao Yuan/ Fang Yu
Center for Drug Safety and Policy Research, Xi’an Jiaotong University
Outcome results
None listed